KFKaren Fieggen

Karen Fieggen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karen Fieggen has a total of 399 co-authors. Here are the top co-authors by number of shared publications:

  • Amanda Krause

    Division of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, The University of the Witwatersrand, Johannesburg, South Africa

    4 shared publications
  • Engela Honey

    Department of Genetics, University of Pretoria, Pretoria, South Africa

    4 shared publications
  • Peter Beighton

    MRC Human Genetics Research Unit, Division of Human Genetics, Institute for Infectious Diseases and Molecular Medicine, Department of Pathology, Faculty of Health Sciences, University of Cape Town, South Africa

    4 shared publications
  • Ambroise Wonkam

    McKusick-Nathans Institute and Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USA

    3 shared publications
  • Anneline Lochan

    Division of Human Genetics, National Health Laboratory Service and School of Pathology, The University of the Witwatersrand, Johannesburg, South Africa

    3 shared publications
  • Jo M. Wilmshurst

    Department of Paediatric Neurology, Red Cross War Memorial Children's Hospital, Neuroscience Institute University of Cape Town Cape Town South Africa

    3 shared publications

Latest Publications

  • Open Access

    Utility of Face2Gene’s DeepGestalt and D-Score applications in paediatric neurodevelopmental disorders in South Africa

    by Zandrè Bruwer, Hendrike Mc Donald, Michal R. Zieff, Emma Eastman, Brigitte Melly, Rizqa Sulaiman-Bardien, Karen Fieggen, Shahida Moosa, Emily O’HEir, Christina Austin Tse, et al.

    Face2Gene is a clinical tool that leverages facial features to aid genetic diagnosis. The DeepGestalt application suggests potential diagnoses based on facial similarity, while the D-Score evaluates likelihood of an individual having dysmorphic features suggestive of a possible genetic diagnosis. Given performance variability across populations and limited data from South Africa, this study assessed clinical utility in South African children with neurodevelopmental disorders (NDDs). Facial photographs from 301 children were analysed. The cohort comprised three groups: 36 children with NDDs with confirmed molecular diagnoses, 176 with NDDs without molecular diagnoses and 89 unaffected children. Diagnostic (recognition) accuracy was measured by whether the confirmed diagnosis appeared in the top-1 or top-10 ranked algorithm-generated suggestions (DeepGestalt). D-Scores were extracted to calculate group differences. Among children with confirmed molecular diagnoses, accuracy was 19% (95% CI: 9–35%) (top-1) and 34% (95% CI: 20–52%) (top-10), improving to 33% (95% CI: 16–56%) and 61% (95% CI: 39–80%) when limited to conditions included in the DeepGestalt training set. One-way ANOVA revealed differences between participants with and without significant dysmorphic features, as assessed by clinicians. The D-Score demonstrated moderate sensitivity (78%, [95% CI: 0.64, 0.88]) and low specificity (42%, [95% CI: 0.38, 0.50]), but high negative predictive value (91%, [95% CI: 0.84, 0.95]), suggesting it may be more useful for ruling out dysmorphism; however, the low specificity indicates a high rate of false positives, even among clinically non-dysmorphic children. These findings suggest that under-representation of African populations may limit clinical performance and equity of AI-based facial phenotyping tools.

  • Open Access

    Cherubism: An African-Focused Review

    by Salma Kabbashi, Imaan A. Roomaney, Martin Douglas-Jones, Karen Fieggen, Nakita Laing, Suvarna Indermun, Manogari Chetty

    Cherubism is a rare fibro-osseous disorder of the jaws that typically presents in early childhood and is recognised as genetically heterogeneous. While the condition is well described in non-African populations, African data and molecular confirmation remain limited. Background/Objectives: This structured narrative review aimed to synthesize published African cases of cherubism by describing patterns of presentation, diagnosis, management, and genetic investigation. Methods: A structured narrative literature review was conducted using PubMed, Scopus, Google Scholar, and African Journals Online. Peer-reviewed case reports and case series describing cherubism in African patients were included. Data extraction followed predefined criteria, capturing demographic features, age at onset and presentation, clinical, radiological and histological findings, management strategies, and the use of molecular genetic testing. Findings were synthesised descriptively. Results: Fourteen studies reporting 20 individual cases from eight African countries were identified, with the majority originating from North Africa. Although symptom onset most commonly occurred in early childhood, the median age at presentation for management was 13.75 years, suggesting delayed access to care. Molecular genetic testing was reported in only two cases, while most diagnoses relied on clinical, radiological, and histopathological features. Surgical intervention was commonly described, with fewer cases managed conservatively. Conclusions: Within the limitations of a structured narrative review based predominantly on published case reports and case series, and constrained by the scarcity of molecularly confirmed cases, the available African literature on cherubism remains limited in scope, geographically skewed, and characterised by incomplete genetic reporting. Recurring features include delayed presentation, reliance on clinical diagnosis, and limited use of molecular testing. These observations reflect gaps in reporting and genetic characterisation rather than population-level patterns, underscoring the need for improved molecular diagnostics, multidisciplinary care, and African registries.

  • Open Access

    Correction: STAC3 disorder: a common cause of congenital hypotonia in Southern African patients

    by Fahmida Essop, Bronwyn Dillon, Felicity Mhlongo, Louisa Bhengu, Thirona Naicker, Lindsay Lambie, Liani Smit, Karen Fieggen, Anneline Lochan, Jessica Dawson, et al.


  • Open Access

    STAC3 disorder: a common cause of congenital hypotonia in Southern African patients

    by Fahmida Essop, Bronwyn Dillon, Felicity Mhlongo, Louisa Bhengu, Thirona Naicker, Lindsay Lambie, Liani Smit, Karen Fieggen, Anneline Lochan, Jessica Dawson, et al.

    STAC3 disorder, or Native American myopathy, is characterised by congenital myopathy, hypotonia, musculoskeletal and palatal anomalies, and susceptibility to malignant hyperthermia. A STAC3 c.851 G > C (p.Trp284Ser) pathogenic variant, common in the Lumbee Native American tribe, has been identified in other populations worldwide, including patients of African ancestry. We report on the frequency of STAC3 c.851 G > C in a cohort of 127 patients presenting with congenital hypotonia that tested negative for spinal muscular atrophy and/or Prader-Willi syndrome. We present a clinical retrospective, descriptive review on 31 Southern African patients homozygous for STAC3 c.851 G > C. The frequencies of various phenotypic characteristics were calculated. In total, 25/127 (20%) laboratory-based samples were homozygous for STAC3 c.851 G > C. A carrier rate of 1/56 and a predicted birth rate of 1/12 500 was estimated from a healthy cohort. A common haplotype spanning STAC3 was identified in four patients. Of the clinical group, 93% had a palatal abnormality, 52% a spinal anomaly, 59% had talipes equinovarus deformity/deformities, 38% had arthrogryposis multiplex congenita, and 22% had a history suggestive of malignant hyperthermia. The novel finding that STAC3 disorder is a common African myopathy has important clinical implications for the diagnosis, treatment and genetic counselling of individuals, with neonatal and/or childhood hypotonia with or without arthrogryposis multiplex congenita, and their families. The spread of this variant worldwide and the allele frequency higher in the African/African-American ancestry than the Admixed Americans, strongly indicates that the STAC3 c.851 G > C variant has an African origin which may be due to an ancient mutation with migration and population bottlenecks.


  • Open Access

    A qualitative study exploring caregivers’ experiences, perspectives, and expectations for precision medicine in epilepsy in South Africa

    by Irene Farisai Muchada, Jo M. Wilmshurst, Nakita Laing, Elin Haf Davies, Karen Fieggen


  • Open Access

    Investigating developmental delay in South Africa: A pragmatic approach

    by K J Fieggen, L A Lambie, K A Donald

    Investigating developmental delay in South Africa: A pragmatic approach


  • Open Access

    Birth outcomes following antiretroviral exposure during pregnancy: Initial results from a pregnancy exposure registry in South Africa

    by Ushma C. Mehta, Cari Van Schalkwyk, Prineetha Naidoo, Arthi Ramkissoon, Otty Mhlongo, Niren R. Maharaj, Niree Naidoo, Karen Fieggen, Michael F. Urban, Shaun Krog, et al.

    Background: In 2013, a pregnancy exposure registry and birth defects surveillance (PER/BDS) system was initiated in eThekwini District, KwaZulu-Natal (KZN), to assess the impact of antiretroviral treatment (ART) on birth outcomes.Objectives: At the end of the first year, we assessed the risk of major congenital malformations (CM) and other adverse birth outcomes (ABOs) detected at birth, in children born to women exposed to ART during pregnancy.Method: Data were collected from women who delivered at Prince Mshiyeni Memorial Hospital, Durban, from 07 October 2013 to 06 October 2014, using medicine exposure histories and birth outcomes from maternal interviews, clinical records and neonatal surface examination. Singleton births exposed to only one ART regimen were included in bivariable analysis for CM risk and multivariate risk analysis for ABO risk.Results: Data were collected from 10 417 women with 10 517 birth outcomes (4013 [38.5%] HIV-infected). Congenital malformations rates in births exposed to Efavirenz during the first trimester (T1) (RR 0.87 [95% CI 0.12–6.4; p = 0.895]) were similar to births not exposed to ART during T1. However, T1 exposure to Nevirapine was associated with the increased risk of CM (RR 9.28 [95% CI 2.3–37.9; p = 0.002]) when compared to the same group. Other ABOs were more frequent in the combination of HIV/ART-exposed births compared to HIV-unexposed births (29.9% vs. 26.0%, adjusted RR 1.23 [1.14–1.31; p 0.001]).Conclusion: No association between T1 use of EFV-based ART regimens and CM was observed. Associations between T1 NVP-based ART regimen and CM need further investigation. HIV- and ART-exposed infants had more ABOs compared to HIV-unexposed infants.


  • The First Case of Riboflavin Transporter Deficiency in sub-Saharan Africa

    by Shaakira Chaya, Marco Zampoli, Diane Gray, Jane Booth, Gillian Riordan, Alvin Ndondo, Karen Fieggen, Jody Rusch, George van der Watt, Komala Pillay, et al.


  • Williams–Beuren syndrome in diverse populations

    by Paul Kruszka, Antonio R. Porras, Deise Helena de Souza, Angélica Moresco, Victoria Huckstadt, Ashleigh D. Gill, Alec P. Boyle, Tommy Hu, Yonit A. Addissie, Gary T. K. Mok, et al.

    Williams–Beuren syndrome (WBS) is a common microdeletion syndrome characterized by a 1.5Mb deletion in 7q11.23. The phenotype of WBS has been well described in populations of European descent with not as much attention given to other ethnicities. In this study, individuals with WBS from diverse populations were assessed clinically and by facial analysis technology. Clinical data and images from 137 individuals with WBS were found in 19 countries with an average age of 11 years and female gender of 45%. The most common clinical phenotype elements were periorbital fullness and intellectual disability which were present in greater than 90% of our cohort. Additionally, 75% or greater of all individuals with WBS had malar flattening, long philtrum, wide mouth, and small jaw. Using facial analysis technology, we compared 286 Asian, African, Caucasian, and Latin American individuals with WBS with 286 gender and age matched controls and found that the accuracy to discriminate between WBS and controls was 0.90 when the entire cohort was evaluated concurrently. The test accuracy of the facial recognition technology increased significantly when the cohort was analyzed by specific ethnic population (P‐value < 0.001 for all comparisons), with accuracies for Caucasian, African, Asian, and Latin American groups of 0.92, 0.96, 0.92, and 0.93, respectively. In summary, we present consistent clinical findings from global populations with WBS and demonstrate how facial analysis technology can support clinicians in making accurate WBS diagnoses.


  • Identification of a single MPV17 nonsense‐associated altered splice variant in 24 South African infants with mitochondrial neurohepatopathy

    by S. Meldau, R.J. De Lacy, G.T.M. Riordan, E.A. Goddard, K. Pillay, K.J. Fieggen, A.D. Marais, G.F. Van der Watt

    MPV17‐related mitochondrial neurohepatopathy is a rare genetic disorder worldwide. We report on a novel pathogenic variant in the MPV17 gene in 24 unrelated neurohepatopathic infants of non‐consanguineous Black South African heritage.Exome sequencing identified homozygosity for a c.106C>T nonsense variant in exon 3 of the human MPV17 gene in 2 unrelated index patients. mRNA analysis revealed transcripts both with and without exon 3, indicating both reduced splice efficiency and premature termination as mechanisms for disease. Carrier frequency in this population was found to be 1 in 68 (95% CI; 1/122‐1/38) with an estimated newborn incidence of 1 in 18 496 (95% CI; 1/59 536‐1/5776). Affected infants all presented with infantile onset neurohepatopathy with none surviving beyond infancy. This description of a relatively common pathogenic variant underlying a previously uncharacterized severe neurohepatopathy in South Africa will engender increased awareness, earlier diagnosis and possibly improve outcome if preventative or specific therapeutic options can be found.